RxDoctor Payments Data

Scott Thomas, MD

Family Medicine · San Antonio, TXNPI 1144273939

Payments from drug & device makers

$12,105in general payments, 2019–2025

Across 593 payments — averaging $20.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • Novo Nordisk$2K
  • Lilly USA, LLC$2K
  • AbbVie$1K
  • Boehringer Ingelheim$934
  • Pfizer$479
  • plus $5K from 36 others

What the payments were for

  • Travel & lodging$2242%
  • Food & beverage$11,88198%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,105 in reported general payments places this provider in the 90th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$55,937
Medicare patients
92
Services billed
587

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide31$38,293
EliquisApixaban28$28,949
JardianceEmpagliflozin24$26,017
MounjaroTirzepatide22$24,463
FarxigaDapagliflozin Propanediol11$15,523
Breztri AerosphereBudesonide/Glycopyr/Formoterol13$11,589
Testosterone11$6,972
Rosuvastatin Calcium155$2,331
PremarinEstrogens, Conjugated12$2,330
Trazodone Hcl30$2,314
Celecoxib16$1,858
SynthroidLevothyroxine Sodium21$1,703
Candesartan Cilexetil19$1,499
Levothyroxine Sodium83$1,200
Testosterone Cypionate23$1,022

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,569$38,29331 claims
PfizerEliquis, Premarin$479$31,27940 claims
AstraZenecaFarxiga, Breztri Aerosphere$1,666$27,11224 claims
Boehringer IngelheimJardiance$934$26,01724 claims
Lilly USA, LLCMounjaro$1,519$24,46322 claims
AbbVieSynthroid$1,236$1,70321 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,760 family medicine providers in Texas.

Other family medicine in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →